Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) CEO Discusses Company Initiatives at O’Cannabiz 2018
- Lexaria Bioscience has its innovative DehydraTECH drug delivery platform
- The company’s DehydraTECH technology is complementary to other R&D being done on cannabinoids
- Lexaria recently attended O’Cannabiz 2018 in Vancouver
A biotech company, Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) offers a unique platform that makes it possible to deliver bioactive substances through oral ingestion. Its DehydraTECH technology accomplishes this without the need for unhealthy inhalational dosing. DehydraTECH uses only GRAS (Generally Recognized as Safe) ingredients and increases bio-absorption by five to 10 times. Based in Kelowna, British Columbia, Lexaria Bioscience is the only company globally with patents issued for the oral delivery of all cannabinoids.
The DehydraTECH drug delivery platform encapsulates cannabinoid compounds in a lipid molecule to eliminate undesirable tastes in cannabinoid edibles. Moreover, this improves bioavailability by protecting the cannabinoid compounds from stomach and first-pass liver metabolism (http://nnw.fm/tRH6H). The technology promotes lower overall dosing and higher effectiveness of lipophilic active molecules.
Recently, Lexaria Bioscience Chief Executive Officer Chris Bunka discussed company progress and plans at O’Cannabiz 2018 (http://nnw.fm/4iCiJ). The O’Cannabiz Conference and Expo took place in Vancouver, British Columbia, in December 2018. The conference featured hundreds of international cannabis companies. Bunka noted (http://nnw.fm/J8u8N) that, in a nutshell, Lexaria makes, “…cannabis products taste better, smell better, and get into your bloodstream a lot more quickly.”
Lexaria Bioscience has provided these benefits to tea and other products. The company removes unwanted tastes as well as smells. Therefore, there is no need to add a lot of sugars or artificial ingredients to mask unpleasant flavors. Lexaria’s tea products sell as ViPova branded premium teas. The company’s other products include TurboCBD high-absorption, full spectrum hemp oil capsules.
Bunka further noted that Lexaria Bioscience has 10 patents granted with over 50 patents pending. Four of the granted patents focus on the delivery of nicotine. The company is not partnering with the tobacco industry. However, Bunka informed that Lexaria is exploring the potential use of its DehydraTECH technology to help people stop smoking.
The company’s technology has been shown to deliver nicotine to the brain quicker than traditional delivery systems. The goal for Lexaria is to put nicotine into some type of oral form to eliminate the need for inhalation and help people curb their smoking habits. DehydraTECH studies in 2018 included two animal studies that delivered pioneering results highlighting the improvements of nicotine delivery to blood plasma and across the blood-brain barrier (http://nnw.fm/4RGjQ).
Lexaria Bioscience’s technology is patent protected for cannabidiol and all other non-psychoactive cannabinoids. The company has patents pending for THC, nonsteroidal anti-inflammatory drugs (NSAIDs), nicotine, other psychoactive cannabinoids and other molecules. An enabling technology and not a competing one, DehydraTECH is a complementary layer that works with the other research and development (R&D) being done on cannabinoids.
Lexaria Bioscience is on the move in its industry. The company is hiring new personnel and building a new laboratory in Canada. It recently created four new subsidiaries, which it is staffing up as well. With more growth on the horizon, Lexaria offers potential profit opportunities to investors wanting to leverage the company’s innovative DehydraTECH drug delivery platform.
For more information, visit the company’s website at www.LexariaBioscience.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- Lexaria Bioscience has its innovative DehydraTECH drug delivery platform
- The company’s DehydraTECH technology is complementary to other R&D being done on cannabinoids
- Lexaria recently attended O’Cannabiz 2018 in Vancouver
A biotech company, Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) offers a unique platform that makes it possible to deliver bioactive substances through oral ingestion. Its DehydraTECH technology accomplishes this without the need for unhealthy inhalational dosing. DehydraTECH uses only GRAS (Generally Recognized as Safe) ingredients and increases bio-absorption by five to 10 times. Based in Kelowna, British Columbia, Lexaria Bioscience is the only company globally with patents issued for the oral delivery of all cannabinoids.
The DehydraTECH drug delivery platform encapsulates cannabinoid compounds in a lipid molecule to eliminate undesirable tastes in cannabinoid edibles. Moreover, this improves bioavailability by protecting the cannabinoid compounds from stomach and first-pass liver metabolism (http://nnw.fm/tRH6H). The technology promotes lower overall dosing and higher effectiveness of lipophilic active molecules.
Recently, Lexaria Bioscience Chief Executive Officer Chris Bunka discussed company progress and plans at O’Cannabiz 2018 (http://nnw.fm/4iCiJ). The O’Cannabiz Conference and Expo took place in Vancouver, British Columbia, in December 2018. The conference featured hundreds of international cannabis companies. Bunka noted (http://nnw.fm/J8u8N) that, in a nutshell, Lexaria makes, “…cannabis products taste better, smell better, and get into your bloodstream a lot more quickly.”
Lexaria Bioscience has provided these benefits to tea and other products. The company removes unwanted tastes as well as smells. Therefore, there is no need to add a lot of sugars or artificial ingredients to mask unpleasant flavors. Lexaria’s tea products sell as ViPova branded premium teas. The company’s other products include TurboCBD high-absorption, full spectrum hemp oil capsules.
Bunka further noted that Lexaria Bioscience has 10 patents granted with over 50 patents pending. Four of the granted patents focus on the delivery of nicotine. The company is not partnering with the tobacco industry. However, Bunka informed that Lexaria is exploring the potential use of its DehydraTECH technology to help people stop smoking.
The company’s technology has been shown to deliver nicotine to the brain quicker than traditional delivery systems. The goal for Lexaria is to put nicotine into some type of oral form to eliminate the need for inhalation and help people curb their smoking habits. DehydraTECH studies in 2018 included two animal studies that delivered pioneering results highlighting the improvements of nicotine delivery to blood plasma and across the blood-brain barrier (http://nnw.fm/4RGjQ).
Lexaria Bioscience’s technology is patent protected for cannabidiol and all other non-psychoactive cannabinoids. The company has patents pending for THC, nonsteroidal anti-inflammatory drugs (NSAIDs), nicotine, other psychoactive cannabinoids and other molecules. An enabling technology and not a competing one, DehydraTECH is a complementary layer that works with the other research and development (R&D) being done on cannabinoids.
Lexaria Bioscience is on the move in its industry. The company is hiring new personnel and building a new laboratory in Canada. It recently created four new subsidiaries, which it is staffing up as well. With more growth on the horizon, Lexaria offers potential profit opportunities to investors wanting to leverage the company’s innovative DehydraTECH drug delivery platform.
For more information, visit the company’s website at www.LexariaBioscience.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
